California Life Sciences Association (CLSA) Applauds U.S. House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act

S. 1379 reauthorizes key federal programs to bolster U.S. public
health preparedness and response capabilities

WASHINGTON & SAN FRANCISCO & SAN DIEGO–(BUSINESS WIRE)–#LifeSciences—California
Life Sciences Association (CLSA), the trade association representing
California’s life sciences sector, applauds today’s U.S. House passage
of S.
1379, the Pandemic and All-Hazards
Preparedness and Advancing Innovation Act (PAHPAI) of 2019.

The legislation is key to strengthening our national preparedness and
response for public health emergencies and accelerating medical
countermeasure research and development. The reauthorization bill was
previously approved by U.S. Senate on May 16, and now goes to President
Trump for his signature. The following statement can be attributed to
Mike Guerra, President & CEO, CLSA:

“California Life Sciences Association (CLSA) applauds today’s U.S. House
passage of the Pandemic and All-Hazards Preparedness and Advancing
Innovation Act (PAHPAI) of 2019, reauthorization legislation that will
strengthen and improve our national preparedness and response for public
health emergencies and accelerate medical countermeasure R&D. The
programs authorized by PAHPAI have been essential to the nation’s
preparedness and response for all populations to threats both
naturally-occurring—like Ebola and pandemic influenza—and deliberate,
such as a chemical, biological, radiological, or nuclear (CBRN) attack.
The Ebola and Zika outbreaks, as-well-as ongoing threats from terrorist
organizations like ISIS, have repeatedly exposed our nation’s continued
vulnerability to bioterror and pandemic threats, demonstrating the need
for robust biodefense preparedness.

“CLSA has worked diligently on behalf of our membership to get this
legislation to the President’s desk. We applaud the leadership of House
Energy and Commerce Health Subcommittee Chairwoman Anna G. Eshoo
(D-Silicon Valley), Congresswoman Susan W. Brooks (R-Ind.), Senator
Richard Burr (R-N.C.), and Senator Bob Casey (D-Pa.) for their
bipartisan work on this important bill. On behalf of California’s life
sciences sector, an industry with over 3,400 firms employing over
311,000 people, we urge President Trump to swiftly sign this bill into
law and bolster our nation’s biodefense preparedness and response
capabilities.”

Click
here to view support letter and learn more about the bill.

• Learn
  More about the California life sciences sector
• View CLSA’s
  Legislative Action Center
• Watch CLSA’s
  Faces of California Biomedical Innovation Web Series
• View Upcoming
  CLSA events
• Meet the
  CLSA Board of Directors

About California Life Sciences Association (CLSA)

California Life Sciences Association (CLSA) is the state’s largest and
most influential life sciences advocacy and business leadership
organization. With offices in Sacramento, San Diego, South San
Francisco, Los Angeles and Washington DC, CLSA works closely with
industry, government, academia and others to shape public policy,
improve access to innovative technologies and grow California’s life
sciences economy. CLSA serves biotechnology, pharmaceutical, medical
device and diagnostics companies, research universities and institutes,
investors and service providers throughout the Golden State. CLSA was
founded in 2015 when the Bay Area Bioscience Association (BayBio) and
the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org,
and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and
YouTube.

Contacts

Media Contact:
California Life Sciences Association (CLSA)
Will
Zasadny | Director, Communications
[email protected] |
619-961-8848